Bioserve is a dynamic organization primarily centred on clinical diagnostics solutions to answer vital questions about an early Cancer diagnosis.
We are India's leading oligosynthesis service provider and have diversified further to Molecular services like DNA/RNA sequencing, utilizing the classic Sanger platforms, as well as the highly advanced Next-Generation sequencing platforms.
Bioserve's core expertise in global biorepository provides leading academic and industry researchers with access to over 600,000 human DNA, tissue, and serum samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients across four continents.
Utilizing BioServe's preclinical molecular services, researchers can identify genetic markers, validate drug targets, and correlate clinical and molecular data to accelerate the development of new and safer drugs.
BioServe's research division offers everything from from nucleic acids processing, DNA synthesis, high throughput sequencing and genotyping, genome wide-scans and gene expression analysis to ready-made large epidemiologically sound case-control studies.
BioServe's customers include nearly every major government research institution, clinical diagnostic labs, hospitals and pharmaceutical company.
With 20+ years of excellence in offering quality services, BioServe has recently been acquired by the Reprocell Group, headquartered in Japan with corporate offices in Europe, USA, and India.
-
Industry
-
Biotechnology
-
Company size
-
51-200 employees
-
Headquarters
-
Hyderabad, Telangana
-
Type
-
Privately Held
-
Founded
-
1994
-
Specialties
-
DNA and RNA Extraction, Genotyping, Real-Time PCR, DNA Synthesis, Next-Generation Sequencing, Oligosynthesis, Molecular Diagnostics, NIPT, Cancer Panels, Clinical Diagnostics, Sanger Sequencing, PGS, Infertility, Genomics, Genetics, Healthcare, Biorepository, Rare diseases, Pharmacogenomics, Reproductive Health, Cancer Diagnosis, Infertility Testing, and Prenatal Testing
